Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90011 + Venetoclax + Azacitidine in AML
NCT04748848Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of pulrodemstat in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Primary endpoints: Adverse Events and Recommended Phase 2 dose. Started Oct 2021; status: terminated.
02
Drugs
pulrodemstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04748848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748848.